European Panel Revokes Symbicort Patent
An appellate panel on Thursday revoked AstraZeneca Plc's European combination patent for the asthma treatment Symbicort, well over two years after the European Patent Office upheld its validity....To view the full article, register now.
Already a subscriber? Click here to view full article